Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Immuron Said Deprioritizing SARS-CoV-2 Research to Focus on Clinical Development of More Advanced Stage Therapeutic Drug Candidates

By Charles Gross
Today, 11:10 AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today announced that it has deprioritized SARS-CoV-2 research to focus on the clinical development of our more advanced stage therapeutic drug candidates.

IMRN

Read More
1 minute read

Immuron Announced US DoD Naval Medical Research Center Received feedback on IND Application for New Campylobacter ETEC Therapeutic; Said IND Does Not Contain Sufficient Information

By Charles Gross
Today, 11:10 AM
:Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today announced that the US Naval Medical Research Center (NMRC) has received feedback from the US Food and Drug Administration following a review of the Investigational New Drug (IND) applica

IMRN

Read More
2 minute read

Immuron Announced US DoD Naval Medical Research Center Submitted IND Application to FDA for New Campylobacter ETEC Therapeutic

By Charles Gross
Today, 11:10 AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today is pleased to announce that the US Naval Medical Research Center (NMRC) has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration for a new oral t

IMRN